

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10599121	
	Filing Date		2006-09-20	
	First Named Inventor	Jakob Felding		
	Art Unit	N/A		
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number	20517/0205421-US0		

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	4624675		1986-11-25	Irmer et al.			
	2	4431725		1984-02-14	Tachikawa et al.			
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	2004242563		2004-12-02	Brugnara et al.			
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
1	1	03/078394	WO		2003-09-25	Lilly Co Eli et al.		<input type="checkbox"/>
2	2	99/26611	WO		1999-06-03	Harvard College et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10599121
Filing Date	2006-09-20
First Named Inventor	Jakob Felding
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	20517/0205421-US0

3	3	1420310	GB		1976-01-07	Ciba Geigy Ag		<input type="checkbox"/>
4	4	05/080335	WO		2005-09-01	President and Fellows of Harvard College		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	SHOICHET, Brian K., et al., "Structure-based Discovery of Inhibitors of Thymidylate Synthase," Science, Vol. 259, No. 5100, 1993, pg. 1445-1450.	<input type="checkbox"/>
	2	PETYUNIN, P.A., "N-Arylamides of Hydroxy Carboxylic Acids and their Transformation into Heterocyclic Compounds. XIII. Use of Arylamides of Alpha-Hydroxy Carboxylic Acids in Intramolecular Dehydrations," Database CA [online] Chemical Abstracts Service, Columbus, Ohio.	<input type="checkbox"/>
	3	NATARAJAN, Amarnath, et al., "3,3-diaryl-1, 3-dihydroindol-2-ones as Antiproliferatives Mediated by Translation Initiation Inhibition," Journal of Medicinal Chemistry, Vol. 47, No. 8, March 9, 2004, pg. 1882-1885.	<input type="checkbox"/>
	4	AKTAS, H., et al., "Depletion of Intracellular Ca ²⁺ Stores, Phosphorylation of eIF2alpha, and Sustained Inhibition of Translation Initiation Mediate the Anticancer Effects of Clotrimazole," Proceedings of the National Academy of Sciences USA, Vol. 95, July 1998, pg. 8280-8285.	<input type="checkbox"/>
	5	BREWER, Joseph W., et al., "Mammalian Unfolded Protein Response Inhibits Cyclin D1 Translation and Cell-Cycle Progression," Proceedings of the National Academy of Sciences USA, Vol. 96, July 1999, pg. 8505-8510.	<input type="checkbox"/>
	6	HARDING, Heather P., et al., "Perk Is Essential for Translational Regulation and Cell Survival During the Unfolded Protein Response," Molecular Cell, Vol. 5, May 2000, pg. 897-904.	<input type="checkbox"/>
	7	NATARAJAN, A., et al., "Novel Arylsulfoanilide-Oxindole Hybrid as an Anticancer Agent that Inhibits Translation Initiation," Journal of Medicinal Chemistry, Vol. 47, No. 21, October 7, 2004, pg. 4979-4982.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10599121
Filing Date	2006-09-20
First Named Inventor	Jakob Felding
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	20517/0205421-US0

8	NAVE, Barbara T., "Mammalian Target of Rapamycin is a Direct Target for Protein Kinase B: Identification of a Convergence Point for Opposing Effects of Insulin and Amino-Acid Deficiency on Protein Translation," Biochem. J., Vol. 344, 1999, pg. 427-431.	<input type="checkbox"/>
9	BEUGNET, Anne, et al., "Regulation of Targets of mTOR (mammalian target of rapamycin) Signalling by Intracellular Amino Acid Availability," Biochem. J., Vol. 372, 2003, pg. 555-566.	<input type="checkbox"/>
10	INOKI, Ken, et al., "TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival," Cell, Vol. 115, November 26, 2003, pg. 577-590.	<input type="checkbox"/>
11	CHERKASOVA, Vera A., "Translational Control by TOR and TAP42 through Dephosphorylation of eIF2alpha kinase GCN2," Genes & Development, Vol. 17, 2002, pg. 859-872.	<input type="checkbox"/>
12	YU, K., et al., "mTOR, a Novel Target in Breast Cancer: The Effect of CCI-779, an mTOR Inhibitor, in Preclinical Models of Breast Cancer," Endocrine-Related Cancer, Vol. 8, 2001, pg. 249-258.	<input type="checkbox"/>
13	HUANG, S. & HOUGHTON, J., "Targeting mTOR Signaling for Cancer Therapy," Current Opinion in Pharmacology, Vol. 3, 2003, pg. 371-377.	<input type="checkbox"/>
14	HEWAWASAM, P., et al., "A General Method for the Synthesis of Isatins: Preparation of Regiospecifically Functionalized Isatins from Anillnes," Tetrahedron Letters, Vol. 35, No. 40, 1994, pg. 7303-7306.	<input type="checkbox"/>
15	RIVALLE, C., & BISAGNI, E., "Ethyl (4-N-Acylaminopyridin-3-yl)glyoxylate and 5-Azaisatin as New Synthons for a Route to Various New Polyheterocycles," J. Heterocyclic Chem., Vol. 34, 1997, pg. 441-444.	<input type="checkbox"/>
16	TATSUGI, Jiro, et al., "An Improved Preparation of Isatins from Indoles," ARKIVOC, 2001, pg. 67-73.	<input type="checkbox"/>
17	DA SILVA, J., et al., "The Chemistry of Isatins: a Review from 1975 to 1999," J. Braz. Chem. Soc., Vol. 12, No. 3, 2001, pg. 273-324.	<input type="checkbox"/>
18	KUBOTA, Hiroyuki, et al., "Rapamycin-Induced Translational Depression of GCN4 mRNA Involves a Novel Mechanism for Activation of the eIF2alpha Kinase GCN2," The Journal of Biological Chemistry, Vol. 278, No. 23, June 2003, pg. 20457-20460.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10599121
Filing Date	2006-09-20
First Named Inventor	Jakob Felding
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	20517/0205421-US0

	19	NOH, Woo-Chul, et al., "Determinants of Rapamycin Sensitivity in Breast Cancer Cells," Clinical Cancer Research, Vol. 10, February 2004, pg. 1013-1023.	<input type="checkbox"/>
--	----	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10599121
Filing Date	2006-09-20
First Named Inventor	Jakob Felding
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	20517/0205421-US0

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/FB/ Flynn Barrison (53,970)	Date (YYYY-MM-DD)	2007-06-01
Name/Print	Louis J. DelJuidice	Registration Number	47522

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.